175 related articles for article (PubMed ID: 3745407)
1. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
Ferrari C; Barbieri C; Caldara R; Mucci M; Codecasa F; Paracchi A; Romano C; Boghen M; Dubini A
J Clin Endocrinol Metab; 1986 Oct; 63(4):941-5. PubMed ID: 3745407
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
Ferrari C; Paracchi A; Romano C; Gerevini G; Boghen M; Barreca A; Fortini P; Dubini A
Clin Endocrinol (Oxf); 1988 Nov; 29(5):467-76. PubMed ID: 2908102
[TBL] [Abstract][Full Text] [Related]
3. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
[TBL] [Abstract][Full Text] [Related]
9. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
Melis GB; Gambacciani M; Paoletti AM; Beneventi F; Mais V; Baroldi P; Fioretti P
J Clin Endocrinol Metab; 1987 Sep; 65(3):541-5. PubMed ID: 3624413
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
[TBL] [Abstract][Full Text] [Related]
11. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
[TBL] [Abstract][Full Text] [Related]
12. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
[TBL] [Abstract][Full Text] [Related]
13. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
[TBL] [Abstract][Full Text] [Related]
14. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
15. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
17. Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
J Biol Regul Homeost Agents; 2004; 18(3-4):291-4. PubMed ID: 15786695
[TBL] [Abstract][Full Text] [Related]
18. Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women.
Giusti M; Lomeo A; Torre R; Sghedoni D; Mazzocchi G; Durante R; Giordano G
Clin Endocrinol (Oxf); 1989 Mar; 30(3):315-21. PubMed ID: 2574083
[TBL] [Abstract][Full Text] [Related]
19. Dopamine agonist therapy in hyperprolactinemia.
Webster J
J Reprod Med; 1999 Dec; 44(12 Suppl):1105-10. PubMed ID: 10649819
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of hyperprolactinemia and acromegaly with lisuride].
Berezin M; Elchalal U; Olchovsky D
Harefuah; 1989 Jun; 116(12):634-7. PubMed ID: 2792946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
